Cognizant Technology Solutions and Gilead Sciences have announced an expansion of their partnership. Cognizant will leverage its Neuro AI generative AI platform to assist Gilead in accelerating value creation, enhancing IT and business processes, and improving operational efficiencies. This initiative aims to provide significant cost savings, which can be reinvested into Gilead's core life sciences business. The collaboration focuses on multiple use cases across customer service, employee interactions, and business value management. Gilead expects to enhance its efficiency by leveraging Cognizant's expertise in AI and advanced technology applications.

Over the last decade, Cognizant has supported Gilead's global IT infrastructure, platforms, applications, and advanced analytics, leading initiatives designed to accelerate its digital transformation. This expanded agreement builds on their collaboration aimed at creating capacity to allow Gilead to continue its focus and mission of discovering and delivering critical medicines for cancer, HIV, and other diseases.

In July 2023, Cognizant and Gilead extended their partnership with a five-year service agreement estimated at $800 million. Under that agreement, Cognizant manages Gilead's global IT infrastructure, platforms, applications, and advanced analytics, leading initiatives designed to accelerate its digital transformation. The collaboration aims to enable Gilead to streamline various parts of its business with the goal of faster time to market for various medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer.

As of January 30, 2025, Cognizant's stock (CTSH) is trading at $82.98, reflecting an increase of 2.21% from the previous close. Gilead Sciences' stock (GILD) is trading at $96.75, up 1.21% from the prior close.